Product Details
Apo-Modafinil
Modafinil100 mg
Tablet
DIN/PIN/NPN
02285398
Manufacturer
Apotex Inc.
Formulary Listing Date
2008-06-27
Unit Price
0.9293
Amount MOH Pays
0.9293
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
C.N.S. Stimulants (28:20:00): Stimulant medication should only be used when diagnostic criteria for narcolepsy or attention deficit disorder have been met and when stimulant medication has been demonstrated to produce clinical benefits. The use of conventional-release medication should almost always precede the use of extended-release preparations.
ATC Code
N06BA07
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02420260 | Teva-Modafinil | 0.9293 | 0.9293 |
02432560 | Mar-Modafinil | 0.9293 | 0.9293 |
02503727 | Jamp Modafinil | 0.9293 | 0.9293 |
02430487 | Auro-Modafinil | 0.9293 | 0.9293 |
02285398 | Apo-Modafinil | 0.9293 | 0.9293 |
02239665 | Alertec | 1.7400 | 0.9293 |
02530244 | Modafinil | 0.9293 | 0.9293 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Central Nervous System Drugs | Modafinil
For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP Drug Request Form: |
Multiple Sclerosis Drugs | Modafinil
For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs |